Certain Balance Sheet Components

6 Months Ended

Sep. 30, 2021

Other Liabilities Disclosure [Abstract]

Cash, Cash Equivalents and Restricted Cash

The following represents a reconciliation of cash and cash equivalents in the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of September 30, 2021 and September 30, 2020, respectively, in the unaudited condensed consolidated statements of cash flows (in thousands):


	September 30,
	2021		2020
Cash and cash equivalents	$	518,163	$	94,210
Restricted cash	10,100		1,987
Total cash, cash equivalents and restricted cash	$	528,263	$	96,197

Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash (maturity of three months or less at the time of purchase). Restricted cash consists of funds held or designated to satisfy the requirements of certain agreements that are restricted in their use and are included in other assets on the unaudited condensed consolidated balance sheets. As of September 30, 2021, restricted cash includes approximately $7.1 million that is held in an escrow fund for use by Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Dainippon Pharma, to manage payments for rebates, chargebacks, and similar fees pursuant to the Market Access Services Agreement (see Note 5(C)).

Inventories

As of September 30, 2021 and March 31, 2021, inventories consisted of the following (in thousands):


	September 30, 2021		March 31, 2021
Raw materials	$	931	$	1,390
Work in process	1,960		773
Finished goods	3,250		448

Total inventories	$	6,141	$	2,611

Accrued Expenses and Other Current Liabilities

As of September 30, 2021 and March 31, 2021, accrued expenses and other current liabilities consisted of the following (in thousands):



	September 30, 2021		March 31, 2021
Accrued compensation-related expenses	$	17,111	$	20,571
Accrued sales discounts, rebates, and allowances	10,493		1,315
Accrued R&D expenses	7,354		8,544
Accrued commercial expenses	7,226		7,770
Accrued other expenses	3,525		5,315
Accrued professional fees	625		935
Deferred product revenue	—		162
Total accrued expenses and other current liabilities	$	46,334	$	44,612